Press Release FDA Posts Briefing Documents for Advisory Committee Meeting to Review Kyndrisa™ (drisapersen) for the Potential Treatment of Duchenne Muscular Dystrophy Amendable to Exon 51 Skipping
Press Release BioMarin Posts Presentation From FDA Advisory Committee Meeting for Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Press Release BioMarin Announces Data Analysis Demonstrating Consistent Efficacy of Kyndrisa™ (drisapersen) in Comparable Patients Across Three Randomized Studies
Press Release European Commission Approves Brineura™ (cerliponase alfa), the First Treatment for CLN2 Disease, a Form of Batten Disease and Ultra-Rare Brain Disorder in Children
Press Release FDA Not Currently Planning to Hold Advisory Committee Meeting for BioMarin’s Pegvaliase Biologics License Application (BLA)
Press Release BioMarin to Participate in Cowen and Company 39th Annual Health Care Conference on March 12 in Boston
Press Release European Commission Approves Palynziq® (pegvaliase injection) for Treatment of Phenylketonuria (PKU) in Patients Aged 16 Years or Older
Press Release BioMarin Announces Proposed Concurrent Public Offerings of Common Stock and Senior Subordinated Convertible Notes
Press Release FDA Posts Briefing Documents for Advisory Committee Meeting Reviewing Vimizim(TM) for the Treatment of Morquio A Syndrome
Press Release BioMarin to Hold Conference Call Today, May 16, at 12:00 PM EDT (18:00 CEST) to Discuss Recent Company Developments and First Quarter 2005 Financial Results
Press Release BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics
Press Release BioMarin Announces Addition of David Pyott, Former Allergan Chairman and CEO, to Company’s Board of Directors
Press Release BioMarin Announces BioMarin RareConnections™ Rebranding and Consolidating BioMarin’s Comprehensive Support and Services for Eligible Rare Disease Patients
Press Release BioMarin Announces Pricing of Concurrent Public Offerings of 9,000,000 Shares of Common Stock and $150 Million Senior Subordinated Convertible Notes
Press Release BioMarin Announces Closing of $295 Million Concurrent Public Offerings of Common Stock and Senior Subordinated Convertible Notes
